Long-Term Topical Steroid Use in Vitiligo: Safety Concerns

"Long-Term Topical Steroid Use in Vitiligo: Safety Concerns" looks closely at a familiar tool, the topical steroid, and the tradeoffs that come with long-term use.

Dr. Taylor asks Dr. Hamzavi to unpack the safety tradeoffs of long-term topical steroid use, since he described ultra-potent steroids on alternate days as his third-line option in the previous discussion. Dr. Hamzavi begins by noting that clinicians rarely see patients actually stick to a strict every-other-day schedule in practice, which itself raises the risk of overexposure. He points to case series and the small number of randomized controlled trials available, which consistently show ultra-potent steroids outperforming mid- and low-potency formulations for repigmentation, explaining why dermatologists reach for the strongest options despite the safety tradeoffs involved.

Those tradeoffs are significant. Dr. Hamzavi describes skin atrophy as an expected local effect of prolonged ultra-potent steroid use, and he warns that steroids can also act on the pituitary axis, altering adrenal gland hormone levels and, in some patients, contributing to adrenal insufficiency. Locally, he has seen acne develop in the specific areas where patients apply the medication, another sign of cumulative steroid exposure. He also flags a paradoxical finding relevant specifically to vitiligo patients: areas surrounding existing depigmentation can themselves develop new hypopigmentation from repeated steroid application, complicating the very repigmentation goal the treatment is meant to achieve.

Taken together, Dr. Hamzavi frames ultra-potent topical steroids as genuinely effective but not free of consequence, requiring clinicians to weigh atrophy, systemic hormonal effects, acne, and peri-lesional hypopigmentation against the benefit of faster repigmentation. That calculus, he suggests, is part of why he reserves steroids for third line, after JAK inhibitors and calcineurin inhibitors, reaching for them mainly when cost or access limits better-tolerated alternatives for patients who still need active treatment.

Our next episode, "Setting Realistic Treatment Goals for Vitiligo Patients," turns to how Dr. Desai frames success and sets goals with his patients.

This video was supported independently by Pfizer.